Wagle, Nikhil

A landscape of driver mutations in melanoma

Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 2,610

Melanoma genome sequencing reveals frequent PREX2 mutations

Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 756

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 481

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 478

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 367

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations

Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 322

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance

Hinohara, K., Wu, H.-J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., Madsen, T., Fassl, A., Egri, S. B., Papanastasiou, M., et al. (2018) · Cancer Cell

Epigenetics and DNA MethylationCancer Cells and Metastasis

Cited by 255

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects

Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., et al. (2018) · Clinical Pharmacology & Therapeutics

Pharmacogenetics and Drug MetabolismGenetic Associations and Epidemiology

Cited by 135

The Fuzzy World of Precision Medicine: Deliberations of a Precision Medicine Tumor Board

McGraw, S. A., Garber, J., Jänne, P. A., Lindeman, N., Oliver, N., Sholl, L. M., Van Allen, E. M., Wagle, N., Garraway, L. A., Joffe, S., et al. (2017) · Personalized Medicine

BRCA gene mutations in cancerGenomics and Rare Diseases

Cited by 20